CytRx, a biopharmaceutical research and development company specializing in oncology, announced encouraging overall survival (OS) results, the secondary endpoint, from its completed multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS).
TiGenix, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced that the European Patent Office (EPO) has issued European Patent EP2292736 relating to an adipose-derived stem cell composition.
WCCT Global, a full service contract research organization was announced to be a strategic partner with Dynport Vaccine Company along with two other CROs for supporting clinical trials to evaluate Anti-Infective Drugs with the NIAID.
Syncona and UCL Business, the wholly-owned technology transfer company of University College London, announce the creation of Autolus Limited, a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours.
Pfizer’s Prevenar 13 gets CHMP positive opinion for prevention of vaccine-type pneumococcal pneumonia in adults
Pfizer announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the indication for Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) be expanded to include the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults 18 years and